comparing the effect of Octreotide on non-variceal GI bleeding in children

Clinical trial for comparing standard treatment for non-variceal upper GI bleeding with and without Octreotide in pediatrics

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120415009475N6

Enrollment

Registered

2019-02-14

Start date

2017-11-22

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal bleeding in children. Acute (erosive) gastritis with haemorrhage

Interventions

Intervention 1: Intervention group: patients will receive 1 to 2 micrograms of Octreotide per kilogram of body weight per hour until the cessation of bleeding. Every 50 micrograms will be infused in 5

Eligibility

Sex/Gender

All

Age

No minimum to 15 Years

Inclusion criteria

Inclusion criteria: diagnosis of GI bleeding age under 15 years hemodynamic stability

Exclusion criteria

Exclusion criteria: abnormal levels of liver enzymes and bilirubin variceal gastrointestinal bleeding Known case of gastrointestinal varices Hepatomegaly or splenomegaly in evaluation chronic liver disease grade C in child pugh score

Design outcomes

Primary

Measure	Time frame
Stop gastrointestinal bleeding. Timepoint: every hour until bleeding stops. Method of measurement: gastric lavage.	—

Secondary

Measure	Time frame
Need for blood transfusion. Timepoint: 24 hours before until 48 hours after intervention. Method of measurement: Volume of blood infusion (milliliter per kilogram).;Hemoglobin level. Timepoint: daily during admission. Method of measurement: complete blood count.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzin Hemmati

Shahid Beheshti University of Medical Sciences

hemmati.azin@ymail.com+98 21 2222 7021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026